165
Views
11
CrossRef citations to date
0
Altmetric
Clinical Focus: Diabetes and Concomitant Disorders

Potential Impact of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Pathophysiology in Type 2 Diabetes Mellitus

, MD

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Avivit Cahn, Simona Cernea & Itamar Raz. (2016) An update on DPP-4 inhibitors in the management of type 2 diabetes. Expert Opinion on Emerging Drugs 21:4, pages 409-419.
Read now

Articles from other publishers (10)

Nuha I. Sweidan, Reema A. Abu Khalaf, Alaa' M. Shatat & Wa'ed A. Hammad. (2022) Therapeutic Potential of Silybum marianum and Pergularia tomentosa Extracts from Jordanian Origin in Diabetes Mellitus . Current Bioactive Compounds 18:8.
Crossref
Reema Abu Khalaf, Maha Awad, Luay Al-Essa, Sara Mefleh, Dima Sabbah, Eveen Al-Shalabi & Ihsan Shabeeb. (2021) Discovery, synthesis and in combo studies of Schiff’s bases as promising dipeptidyl peptidase-IV inhibitors. Molecular Diversity 26:2, pages 1213-1225.
Crossref
Habib Yaribeygi, Stephen L. Atkin, Tannaz Jamialahmadi & Amirhossein Sahebkar. (2020) A Review on the Effects of New Anti-Diabetic Drugs on Platelet Function. Endocrine, Metabolic & Immune Disorders - Drug Targets 20:3, pages 328-334.
Crossref
Shih-Wei Lai, Kuan-Fu Liao, Cheng-Li Lin & Hsien-Feng Lin. (2017) Dipeptidyl Peptidase-4 Inhibitors Use and Relative Risk of Ischemic Cerebrovascular Disease in Type 2 Diabetic Patients in a Case-Control Study. Frontiers in Pharmacology 8.
Crossref
Hina L. Nizami & Sanjay K. Banerjee. 2017. Mechanisms of Vascular Defects in Diabetes Mellitus. Mechanisms of Vascular Defects in Diabetes Mellitus 483 514 .
Elizabeth Osei, Susanne Fonville, Adrienne A. M. Zandbergen, Paul J. A. M. Brouwers, Laus J. M. M. Mulder, Hester F. Lingsma, Diederik W. J. Dippel, Peter J. Koudstaal & Heleen M. den Hertog. (2015) Metformin and sitAgliptin in patients with impAired glucose tolerance and a recent TIA or minor ischemic Stroke (MAAS): study protocol for a randomized controlled trial. Trials 16:1.
Crossref
Jinsong Geng, Hao Yu, Yiwei Mao, Peng Zhang & Yingyao Chen. (2015) Cost Effectiveness of Dipeptidyl Peptidase-4 Inhibitors for Type 2 Diabetes. PharmacoEconomics 33:6, pages 581-597.
Crossref
Antoni Sicras-MainarRuth Navarro-Artieda. (2015) Response: Economic Impact of Combining Metformin with Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients with Renal Impairment in Spanish Patients ( Diabetes Metab J 2015;39:74-81) . Diabetes & Metabolism Journal 39:2, pages 173.
Crossref
Sho-ichi Yamagishi, Kei Fukami & Takanori Matsui. (2015) Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications. Cardiovascular Diabetology 14:1, pages 2.
Crossref
Peter Clifton. (2014) Do Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Cause Heart Failure?. Clinical Therapeutics 36:12, pages 2072-2079.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.